Thermo Fisher opens $160m MA purification tech plant

As part of a multiyear $650 million CAPEX spend, Thermo Fisher has brought an 85,000 square-foot purification product plant online.

Dan Stanton, Managing editor

September 21, 2022

1 Min Read
Thermo Fisher opens $160m MA purification tech plant
Thermo Fisher's site in Chelmsford, Massachusetts

As part of a multiyear $650 million CAPEX spend across its bioprocessing business, Thermo Fisher has brought an 85,000 square-foot purification product plant online.

The facility in Chelmsford, Massachusetts opened its doors this week, and is set to supply biomanufacturing customers with downstream technologies, specifically for the purification of biologics and vaccines.

“This market continues to grow and the world’s leading biopharmaceutical companies depend on our technologies, services and expertise to help deliver life changing therapies to patients,” said Jean Luo, vice president and general manager, purification and pharma analytics, Thermo Fisher Scientific.


Thermo Fisher’s site in Chelmsford, Massachusetts

“The Chelmsford site will help us provide our customers with the critical resin materials they need as they scale up production and bring new innovations to market. This ultimately helps ensure more patients get the treatments they need faster.”

The facility is located at the Chelmsford site – acquired for $11.68 million by Thermo Fisher in 2020 – is part of the firm’s global bioprocessing supply network, which has been subjected to ongoing investments over the past few years, including a $650 million multi-year CAPEX plan announced in 2021.

Within the past few weeks, Thermo Fisher has opened a $105 million single-use facility in Nashville, Tennessee and a $180 million viral vector facility in Plainville, Massachusetts.

Other expansions include a drug substance facility in St Louis, Missouri, a fill-finish plant in Greenville, North Carolina, as well as single-use scale-up in Singapore, and Bedford (Massachusetts), Innchinnan (UK).

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like